Please assess the completion status of the following clinical trial:

Trial Title: Exploration of Pupil Dilation in Horner's Patients Taking Flomax

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Horner's Syndrome~2. History of taking an alpha blocker (tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin) medication~Exclusion Criteria:~1. Subjects with untreated hypertension~2. Subjects with thyrotoxicosis~3. Pregnant women~4. Prisoners~5. Inability to consent~6. Subjects with anatomical narrow angles who have never had a dilated exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 10% phenylephrine (Type: OTHER): All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).